Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2024-08-26 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2024年股权激励计划（草案）
Board/Management Information Classification · 95% confidence The document is a detailed disclosure of a company's stock incentive plan, specifically a restricted stock incentive plan. It includes legal references, definitions, purpose, management structure, scope of incentive recipients, stock quantities, pricing, vesting conditions, and performance targets. The document is comprehensive and regulatory in nature, focusing on the company's equity incentive scheme rather than financial results or earnings. It is not an announcement of a report but a full disclosure document. This type of document aligns with filings related to management and board information, especially concerning senior management incentives and equity plans. Therefore, the most appropriate classification is 'Board/Management Information' (MANG).
2024-08-26 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the year 2024. It contains detailed financial data including income, profit, assets, liabilities, and operational performance for the period January 1, 2024 to June 30, 2024. The document includes comprehensive financial statements, management discussion of business operations, risk factors, and other substantive financial and operational information. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fourth board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other reports such as the 2024 semi-annual report and related disclosures. The document focuses on board decisions, including approval of reports, equity incentive plans, and proposals to be submitted to the shareholders' meeting. It does not contain the actual semi-annual financial report or detailed financial data but rather the board's resolutions and approvals related to these reports and plans. Therefore, this document is best classified as Board/Management Information (MANG), as it primarily announces board meeting resolutions and management decisions.
2024-08-26 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of several proposals including the 2024 semi-annual report, a special report on the use of raised funds, and a 2024 equity incentive plan draft. The document references the actual reports and plans being disclosed separately on the Beijing Stock Exchange information platform with specific announcement numbers. The document itself does not contain the full semi-annual report or detailed financial data but rather the resolutions approving these reports and plans. The document length is 3073 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board resolutions and references other filings but does not contain the full reports themselves.
2024-08-26 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder structure, and other operational details. The document length is over 5,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
关于独立董事公开征集表决权公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement by independent directors of Chengdu Oukang Pharmaceutical Co., Ltd. regarding the solicitation of voting rights for the 2024 first extraordinary general meeting of shareholders. It details the agenda items for the meeting, the reasons for soliciting votes, the procedures for shareholders to authorize voting rights, and the legal compliance of the solicitation. The document is not a report of financial results, audit, or management discussion, nor is it a transcript or presentation. It is an official announcement related to voting rights solicitation for a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and contains detailed procedural information about voting rights solicitation, not just a brief notice or report publication announcement. Therefore, the best classification is DVA with high confidence.
2024-08-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.